Connect with us

Business

As Canadian medical cannabis slump continues, survey says cost an issue

Published

on

The high cost of medical cannabis poses major obstacles for Canadian patients, even as recreational marijuana prices remain low, a new survey of thousands of Canadians suggests.

The finding comes as a slump in consumer spending on regulated medical cannabis in Canada continues, with Statistics Canada data showing sales worth 101 million Canadian dollars (roughly $75 million) in the fourth quarter of 2022.

That CA$101 million figure represents a 3.8% decline from the same quarter in 2021 and a 34% tumble from the fourth quarter of 2018, when Canada legalized recreational cannabis.

It equals 7.5% of legal recreational cannabis spending in the fourth quarter of 2022.

The Medical Cannabis Access Survey released this month by a group of Canadian university researchers and medical marijuana patient groups surveyed 5,744 respondents over five months in 2022, mostly “daily consumers of medical cannabis with more than 10 years of experience.”

Study is ‘one of largest’

The online survey did not use a random sample, so its findings cannot be generalized to the Canadian population as a whole.

However, the large sample size makes the study “one of the largest to examine Canadians’ medical cannabis use and experiences in the past decade,” according to the report.

As MJBizDaily has reported, some Canadian cannabis companies are focusing on patients covered by employee benefit plans as a strategy to grow their share of the higher-margin medical marijuana market.

However, few survey respondents had their medical cannabis covered by such plans.

“Despite over half of individuals with current medical (cannabis) authorization having some form of private health insurance, only 6% reported being successful in receiving reimbursement for medical cannabis-related expenses,” the survey noted.

The survey found that median out-of-pocket spending on medical cannabis was CA$125 per month, and 39% of respondents spent more than CA$200 per month.

Those costs are “a travesty,” said Dr. Michael Dworkind, a palliative care physician and medical director of Sante Cannabis, a Montreal medical marijuana clinic and one of the groups behind the survey.

“In our socialized health care system, people should not be paying for their drugs,” Dworkind told MJBizDaily.

Dworkind said he has patients who spend CA$250 per month on medical cannabis.

“They have to give up eating,” he said. “These are people who lose their jobs because they’re disabled – car accidents, work accidents and so on.

“It’s tragic that this is a huge barrier.”

The survey also found that respondents who earned less than CA$35,000 per year spent roughly CA$50 more per month on medical cannabis than higher-income respondents.

Among the 3.5% of respondents who had used medical cannabis in the past but no longer did, the most common reason given for stopping was the cost (48%).

In Quebec, where Sante Cannabis is based, the provincial government’s Société québécoise du cannabis (SQDC) recreational cannabis retail monopoly keeps prices low to compete against the illicit market.

Dworkind said some patients buy cannabis from SQDC’s recreational stores “instead of going to the licensed producers who (Sante Cannabis is) aligned with, who give us research and development dollars so that we can stay alive.”

“Our doctors are paid on Medicare, but everything else is paid through our licensed producers,” Dworkind explained.

“Research money is dried up,” he continued.

“Five years ago, we were getting significant amounts of money for our research.

“Now they say, ‘Our budgets can’t handle it.'”

Medical cannabis program favored

Regardless of the cost challenges reported by survey respondents, “the majority of individuals in this study supported the continuation of the medical cannabis program in Canada,” according to the report.

“Individuals reported that being able to claim medical cannabis-related expenses on tax forms, receiving compassionate pricing from licensed sellers, and being allowed higher possession limits were important aspects of the medical cannabis program.”

Respondents also suggested that medical cannabis should be made available through pharmacies, according to the report.

“Being able to consult a pharmacist about dose and product, discuss possible interactions with other medications, and obtain medical cannabis in a timely manner were all reasons provided for allowing medical cannabis to be distributed through pharmacies in Canada.”

Major Canadian pharmacy chain Shoppers Drug Mart announced it was exiting its medical cannabis distribution business in late March.

Source: https://mjbizdaily.com/cost-a-factor-in-canadian-medical-cannabis-slump-survey-shows/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News